Aravive to Present at the H.C. Wainwright Virtual BioConnect Conference
January 04 2021 - 4:05PM
Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology
company developing transformative therapeutics, today
announced the Company will present at the H.C. Wainwright Virtual
BioConnect Conference taking place January 11-14, 2021. Aravive’s
presentation will be available for viewing on January 11, 2021.
The webcast and audio archive of the presentation
will be available at http://ir.aravive.com. An archived replay
of the webcast will be available for 90 days following the
presentation.
About AraviveAravive, Inc. is
a clinical-stage oncology company developing transformative
therapeutics designed to halt the progression of life-threatening
diseases. Aravive’s lead therapeutic, AVB-500, is an ultra-high
affinity decoy protein that targets the GAS6-AXL signaling pathway
associated with tumor cell growth. Aravive recently successfully
completed a Phase 1b trial of AVB-500 in platinum resistant ovarian
cancer and selected 15 mg/kg as the dose for the Phase 3 trial.
While the Phase 1b trial of AVB-500 in platinum resistant ovarian
cancer was a safety trial and not powered to demonstrate efficacy,
all 5 patients in the 15 mg/kg cohort experienced clinical benefit,
with 1 complete response, 2 partial responses, and 2 stable
disease. The Company has initiated and is recruiting for its Phase
1b/2 trial in patients with clear cell renal cell carcinoma. For
more information, please visit www.aravive.com.
Contacts:Media:Sheryl Seapy,
W2Osseapy@w2ogroup.com(213) 262-9390
Investors:Luke Heagle, W2O lheagle@w2ogroup.com
(910) 726-1372
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Apr 2023 to Apr 2024